Biohaven is a high-risk clinical biotech whose $400 million SK licensing deal funds pivotal catalysts, while epilepsy, obesity, and degrader readouts create substantial but highly binary upside.
Overview
Biohaven Ltd. is a clinical-stage biotechnology company focused on neurodegenerative, metabolic, autoimmune, and oncology therapies. It has no FDA-approved products and therefore no recurring commercial product revenue; instead, it has historically relied on licensing payments, milestones, and collaboration funding. The August 2026 SK Biopharmaceuticals transaction materially improves the model by providing $400 million of near-term cash, up to $150 million of milestones, tiered U.S. royalties, and partner assumption of ex-U.S. development costs and up to $245 million of legacy obligations. **The near-term investment case is defined by H2 2026 clinical readouts** for opakalim in refractory focal epilepsy and taldefgrobep alfa in obesity, alongside Phase 3 advancement of BHV-1300 and BHV-1400. Q2 2026 revenue was $0, GAAP net loss was $137.3 million, and cash was $270.5 million, but R&D fell 45.3% year over year to $100.8 million. Valuation is pipeline-driven: consensus long-term revenue growth exceeds 70% annually through 2031, versus a current reference price of $15.41. The report’s probability-weighted five-year target is $30.04, with substantial downside if trials fail.